2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. 상품명 효과 Purity Chemical Structure
  • HY-12085S2
    (Rac)-Apremilast-d5
    (Rac)-Apremilast-d5 is a deuterium labeled (R)-Apremilast. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.
    (Rac)-Apremilast-d<sub>5</sub>
  • HY-155944
    Isbufylline
    		Inhibitor
    Isbufylline is a Phosphodiesterase inhibitor. Isbufylline is orally available. Isbufylline can be used in the research of respiratory diseases and inflammation such as asthma and pneumonia.
    Isbufylline
  • HY-135746R
    OR-1896 (Standard)
    		Inhibitor
    7-epi-Taxol (Standard) is the analytical standard of 7-epi-Taxol. This product is intended for research and analytical applications. 7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting microtubule bundle formation and against microtubule depolymerization.
    OR-1896 (Standard)
  • HY-RS10206
    Pde12 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Pde12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pde12 Mouse Pre-designed siRNA Set A
  • HY-119601
    GRI918013
    		Inhibitor
    GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus.
    GRI918013
  • HY-B0763S1
    Ibudilast-d7
    		Inhibitor
    Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.
    Ibudilast-d<sub>7</sub>
  • HY-W700638A
    Benafentrine maleate
    		Inhibitor
    Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor.
    Benafentrine maleate
  • HY-N13132
    Hellicoside
    		Inhibitor
    Hellicoside is a natural product that can be obtained from plantain. Hellicoside has inhibitory activity against cAMP phosphodiesterase and 5-lipoxygenase.
    Hellicoside
  • HY-175047
    Enpp-1-IN-26
    		Inhibitor
    Enpp-1-IN-26 (Compound 4e) is an ENPP1 inhibitor with an IC50 of 0.188 μM. Enpp-1-IN-26 enhances IFN-β expression in vivo by preventing ENPP1 from hydrolyzing cGAMP. Enpp-1-IN-26 can be used in the research of metastatic breast cancer.
    Enpp-1-IN-26
  • HY-B1726
    Phenacaine
    		Inhibitor 99.68%
    Phenacaine (Holocaine) is a local agent that can suppress or relieve pain. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca2+-ATPase and cyclic nucleotide phosphodiesterases from brain and heart.
    Phenacaine
  • HY-148625
    PDE9-IN-2
    		Inhibitor
    PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
    PDE9-IN-2
  • HY-90009AS1
    Tadalafil-13C2,d3-1
    Tadalafil-13C2,d3-1 (IC-351-13C2,d3-1) is the deuterium and 13C-labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a PDE5 inhibitor with an IC50 value of 1.8 nM.
    Tadalafil-13</sup>C<sub>2</sub>,d<sub>3</sub>-1
  • HY-119316
    CM-414
    		Inhibitor
    CM-414 is a brain-penetrant phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC50s of 60 nM, 91 nM, 310 nM, 322 nM and 490 nM for PDE5, HDAC6, HDAC1, HDAC3 and HDAC2, respectively. CM-414 diminishes brain Aβ and tau phosphorylation (pTau) level in Tg2576 mice. CM-414 can be used for the study of Alzheimer's disease (AD).
    CM-414
  • HY-125738
    Obscurolide A1
    		Inhibitor
    Obscurolide A1 is a Phosphodiesterase (PDE) inhibitor (IC50=8 mM) that can be obtained from Streptomyces viridochromogenes culture. Obscurolide A1 has the potential to study neurological and inflammatory diseases.
    Obscurolide A1
  • HY-145064
    Enpp-1-IN-6
    		Inhibitor
    Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51).
    Enpp-1-IN-6
  • HY-W751650
    Sildenafil-d3 citrate
    Sildenafil-d3 citrate (UK-92480-d3 citrate) is the deuterium labeled Sildenafil citrate (HY-15025A). Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.
    Sildenafil-d<sub>3</sub> citrate
  • HY-P4108C
    Cys-TAT-HA2
    Cys-TAT-HA2 is a conjugate of Cys and TAT-HA2 (HY-P4108). Cys-TAT-HA2 is a transduction complex that can be introduced protein (such as Cardiac troponin C) into the cytoplasm of living cells. Cys-TAT-HA2 can be used for live tracking of exogenous proteins research.
    Cys-TAT-HA2
  • HY-18252S1
    Avanafil-13C5,15N,d2
    		Inhibitor
    Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N,d<sub>2</sub>
  • HY-148291
    BrP-LPA sodium
    		Inhibitor
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.
    BrP-LPA sodium
  • HY-171780
    ASP9831
    		Inhibitor
    ASP9831 is an orally active PDE4 inhibitor. ASP9831 inhibits LSP-induced TNF-α production and has anti-inflammatory activity. ASP9831 can be used in fatty liver disease research.
    ASP9831
Cat. No. 상품명 / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.